Millennium Management LLC Acquires 523,571 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Millennium Management LLC lifted its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 357.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 670,065 shares of the company's stock after acquiring an additional 523,571 shares during the period. Millennium Management LLC owned 1.17% of Ginkgo Bioworks worth $6,580,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at approximately $29,000. KBC Group NV acquired a new position in Ginkgo Bioworks in the fourth quarter valued at $31,000. KLP Kapitalforvaltning AS acquired a new stake in Ginkgo Bioworks during the fourth quarter worth about $46,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter worth about $116,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of Ginkgo Bioworks in the fourth quarter worth about $144,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Stock Down 4.0%

NYSE:DNA traded down $0.29 during trading hours on Friday, reaching $6.96. 769,651 shares of the stock were exchanged, compared to its average volume of 1,454,051. The firm has a 50 day simple moving average of $7.19 and a 200-day simple moving average of $9.00. The stock has a market capitalization of $407.38 million, a P/E ratio of -0.53 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $23.24.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative net margin of 298.78% and a negative return on equity of 58.54%. The business had revenue of $48.32 million for the quarter, compared to analysts' expectations of $38.70 million. As a group, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.